SVBI (1786) reported revenue of NT$78.3 million for Oct 2026, +1.6% year on year and +28.1% from the previous month. Revenue for Jan–Oct 2026 was NT$697.3 million (-2.1% year on year).
In Oct 2026, it ranked No. 88 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$78.3 million | +1.6% | +28.1% |
| Sep 2026 | NT$61.1 million | +1.3% | -7.9% |
| Aug 2026 | NT$66.4 million | -22.7% | -11.8% |
| Jul 2026 | NT$75.2 million | +0.0% | +1.0% |
| Jun 2026 | NT$74.4 million | +1.0% | +1.5% |
| May 2026 | NT$73.4 million | +1.0% | +16.0% |
| Apr 2026 | NT$63.2 million | +0.1% | -15.5% |
| Mar 2026 | NT$74.8 million | +0.8% | +35.8% |
| Feb 2026 | NT$55.1 million | +0.1% | -26.9% |
| Jan 2026 | NT$75.4 million | +0.5% | -20.0% |
| Dec 2025 | NT$94.2 million | +1.2% | +17.5% |
| Nov 2025 | NT$80.2 million | -1.7% | +4.1% |
| Oct 2025 | NT$77 million | -4.4% | +27.6% |
| Sep 2025 | NT$60.3 million | +0.0% | -29.7% |
| Aug 2025 | NT$85.9 million | +0.0% | +14.2% |
| Jul 2025 | NT$75.2 million | -1.1% | +2.0% |
| Jun 2025 | NT$73.7 million | -2.5% | +1.6% |
| May 2025 | NT$72.6 million | -0.9% | +14.9% |
| Apr 2025 | NT$63.2 million | +2.3% | -14.9% |
| Mar 2025 | NT$74.2 million | +5.2% | +34.8% |
| Feb 2025 | NT$55.1 million | +9.0% | -26.6% |
| Jan 2025 | NT$75 million | +1.0% | -19.4% |
| Dec 2024 | NT$93.1 million | +14.7% | +14.2% |
| Nov 2024 | NT$81.5 million | +31.4% | +1.2% |
| Oct 2024 | NT$80.6 million | +34.2% | +33.6% |
Jan–Oct 2026 cumulative: NT$697.3 million (-2.1% YoY)
Other Biotech & Medical companies
Compare with peers: SVBI vs PEC / SVBI vs Lotus Pharm / SVBI vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16